Diabetes in patients with idiopathic parkinson's disease

Diabetes Care

Volumn 31, Issue 9, 2008, Pages 1808-1812

  Becker, Claudia ^a   Brobert, Gunnar P ^b   Johansson, Saga ^c,d   Jick, Susan S ^e   Meier, Christoph R ^a,e  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARKINSON DISEASE; PREVALENCE; RISK; RISK ASSESSMENT; UNITED KINGDOM; COMORBIDITY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMORBIDITY; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE; RISK ASSESSMENT;

EID: 56149114786     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0479     Document Type: Article

References (29)

1. Greenamyre JT, Hastings TG: Biomedicine. Parkinson's: divergent causes, convergent mechanisms. Science 304:1120-1122, 2004
2. Samii A, NuttJG, Ransom BR: Parkinson's disease. Lancet 363:1783-1793, 2004
3. Kelley DE, He J, Menshikova EV, et al.: Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944-2950, 2002
4. Petersen KF, Befroy D, Dufour S, et al.: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140-1142, 2003
5. Petersen KF, Dufour S, Befroy D, et al.: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664-671, 2004
6. Ristow M: Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 82:510-529, 2004
7. Craft S, Watson GS: Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3:169-178, 2004
8. Powers KM, Smith-Weller T, Franklin GM, et al.: Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 12:185-189, 2006
9. Scigliano G, Musicco M, Soliveri P, et al.: Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37:1184 -1188, 2006
10. Pressley JC, Louis ED, Tang MX, et al.: The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 60:87-93, 2003
11. Hu G, Jousilahti P, Bidel S, et al.: Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30:842-847, 2007
12. Simon KC, Chen H, Schwarzschild MA, et al.: Hypertension, hypercholesterolemia, diabetes, and the risk of Parkinson disease. Neurology 69:1688-1695, 2007
13. Van Woert MH, Mueller PS: Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa. Clin Pharmacol Ther 12:360-367, 1971
14. Sirtori CR, Bolme P, Azarnoff DL: Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med 287:729-733, 1972
15. Luo S, Liang Y, Cincotta AH: Intracerebro-ventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinol- ogy 69:160-166, 1999
16. Wood L, Martinez C: The general practice research database: role in pharmacovigilance. Drug Saf 27:871-881, 2004
17. Lawson DH, Sherman V, Hollowell J: The General Practice Research Database: Scientific and Ethical Advisory Group. QJM 91:445-452, 1998
18. Jick H: A database worth saving. Lancet 350:1045-1046, 1997
19. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al.: Validity of the general practice research database. Pharmacotherapy23:686-689, 2003
20. Walley T, Mantgani A: The UK General Practice Research Database. Lancet 350: 1097-1099, 1997
21. Schade R, Andersohn F, Suissa S, et al.: Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356: 29-38, 2007
22. Hernan MA, Takkouche B, Caamano-Isorna F, et al.: A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52:276-284, 2002
23. Hernan MA, Logroscino G, Rodriguez LA: A prospective study of alcoholism and the risk of Parkinson's disease. J Neurol 251 (Suppl. 7):VII14-VI17, 2004
24. Hernan MA, Logroscino G, Garcia Rodriguez LA: Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66:1097-1099, 2006
25. Alonso A, Rodriguez LA, Logroscino G, et al.: Gout and risk of Parkinson disease: a prospective study. Neurology 69:1696-700, 2007
26. Stumvoll M, Goldstein BJ, van Haeften TW: Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333-1346, 2005
27. Chen H, Zhang SM, Schwarzschild MA, et al.: Obesity and the risk of Parkinson's disease. Am J Epidemiol 159:547-555, 2004
28. Hu G, Jousilahti P, Nissinen A, Antikainen R, et al.: Body mass index and the risk of Parkinson disease. Neurology 67:1955-1959, 2006
29. Abbott RD, Ross GW, White LR et al.: Midlife adiposity and the future risk of Parkinson's disease. Neurology 59:1051-1057, 2002